Início › Câncer de Ovário › Connecticut

Ensaios clínicos de Câncer de Ovário em Connecticut

28 estudos para Câncer de Ovário estão buscando participantes em locais em Connecticut.

Cidades em Connecticut

Texto oficial do estudo (Inglês)

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Yale Cancer Center, New Haven

RecrutandoFase 1/2

Idades 12 e acima · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT04585750

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

Yale Cancer Center, New Haven

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 1 de out. de 2026 · NCT06172478

Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors

Yale University - Yale University School of Medicine, New Haven

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 29 de set. de 2026 · NCT07360314

A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Site 0158 - Hartford HealthCare, Hartford

RecrutandoFase 2

Idades 18 e acima · Mulheres · Atualizado em 29 de set. de 2026 · NCT05128825

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

Danbury Hospital, Western Connecticut Health Network /ID# 274783, Danbury
Yale University School of Medicine /ID# 275794, New Haven
Norwalk Hospital /ID# 274561, Norwalk

RecrutandoFase 2

Idades 18 e acima · Mulheres · Atualizado em 29 de set. de 2026 · NCT06890338

Study of AVZO-021 in Patients With Advanced Solid Tumors

Avenzo Therapeutics Recruiting Site, New Haven

RecrutandoFase 1/2

Idades 18 e acima · Todos os sexos · Atualizado em 28 de set. de 2026 · NCT05867251

A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors

Kivu Trial Site, New Have

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 24 de set. de 2026 · NCT07229313

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

UConn Health, Farmington

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT07213804

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

Yale University, Yale Cancer Center, New Haven

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 21 de set. de 2026 · NCT05983432

FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

Yale Cancer Center, New Haven

RecrutandoFase 1/2

Idades 18 e acima · Todos os sexos · Atualizado em 14 de set. de 2026 · NCT06303505

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

Yale-New Haven Hospital-Smilow Cancer Hospital at Yale-New Haven ( Site 0001), New Haven

RecrutandoFase 3

Idades 18 e acima · Mulheres · Atualizado em 3 de set. de 2026 · NCT06824467

Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer

Danbury Hospital, Danbury

RecrutandoFase 3

Idades 18 e acima · Mulheres · Atualizado em 1 de set. de 2026 · NCT07564141

Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity

Smilow Cancer Hospital-Derby Care Center, Derby
Smilow Cancer Hospital Care Center-Fairfield, Fairfield
Smilow Cancer Hospital Care Center at Greenwich, Greenwich
e mais 8

RecrutandoFase 2/3

Idades 18 e acima · Todos os sexos · Atualizado em 19 de ago. de 2026 · NCT07001748

A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

Normunity Investigational Site, New Haven

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 18 de ago. de 2026 · NCT07182149

A Study of PHST001 in Advanced Solid Tumors

Yale Cancer Center, New Haven

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 12 de ago. de 2026 · NCT06840886

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

Danbury Hospital, Danbury
Smilow Cancer Hospital Care Center at Greenwich, Greenwich
Hartford Hospital, Hartford
e mais 5

Recrutando

Idades de 35 a 50 · Mulheres · Atualizado em 7 de ago. de 2026 · NCT04251052

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

Danbury Hospital, Danbury
Smilow Cancer Hospital Care Center-Fairfield, Fairfield
Smilow Cancer Hospital Care Center at Greenwich, Greenwich
e mais 8

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 7 de ago. de 2026 · NCT06580314

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Yale University School of Medicine, New Haven

RecrutandoFase 2/3

Idades 18 e acima · Todos os sexos · Atualizado em 28 de jul. de 2026 · NCT06161025

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

Norwalk Hospital, Norwalk

RecrutandoFase 2

Idades 8 e acima · Todos os sexos · Atualizado em 27 de jul. de 2026 · NCT05503797

Trial of Exercise and Lifestyle for Women With Ovarian and Endometrial Cancer

Yale University, New Haven

Recrutando

Idades 18 e acima · Mulheres · Atualizado em 20 de jul. de 2026 · NCT05761561

A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer

Yale University, New Haven

RecrutandoFase 1

Idades 18 e acima · Mulheres · Atualizado em 6 de jul. de 2026 · NCT07226427

Integrated Cancer Repository for Cancer Research

Hartford HealthCare Cancer Institute at Manchester Medical Hospital, Manchester

RecrutandoEstudo observacionalVoluntários saudáveis bem-vindos

Idades de 19 a 110 · Todos os sexos · Atualizado em 29 de jun. de 2026 · NCT02012699

Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

Yale University, Yale Cancer Center, New Haven

RecrutandoFase 1/2

Idades 18 e acima · Todos os sexos · Atualizado em 23 de jun. de 2026 · NCT06993844

Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer

Hartford Hospital, Hartford
Smilow Cancer Hospital at Yale- New Haven, New Haven
Yale University School of Medicine, New Haven

RecrutandoFase 3

Idades 18 e acima · Mulheres · Atualizado em 16 de abr. de 2026 · NCT05659381

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

Yale University, Yale Cancer Center, New Haven

RecrutandoFase 1/2

Idades 18 e acima · Todos os sexos · Atualizado em 27 de mar. de 2026 · NCT06395519

A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors

Yale University, New Haven

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 14 de jan. de 2026 · NCT06234423

CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.

Smilow Cancer Hospital at Yale - New Haven, New Haven

RecrutandoFase 2

Idades 18 e acima · Mulheres · Atualizado em 23 de dez. de 2025 · NCT06690775

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Massive Bio SYNERGY-AI site, Hartford
Massive Bio SYNERGY-AI site, Norwalk

RecrutandoEstudo observacional

Todas as idades · Todos os sexos · Atualizado em 28 de out. de 2025 · NCT03452774

Fonte: ClinicalTrials.gov, dados obtidos em 5 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.